Gynecological health of females with congenital heart disease

International Journal of Cardiology

Volumn 98, Issue 3, 2005, Pages 379-387

  Canobbio, Mary M ^a   Perloff, Joseph K ^a   Rapkin, Andrea J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Congenital heart disease; Contraception; Menstruation

Indexed keywords

AMOXICILLIN; ANTICOAGULANT AGENT; BISPHOSPHONIC ACID DERIVATIVE; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL; GESTAGEN; LATEX; LEVONORGESTREL; LOW DOSE ORAL CONTRACEPTIVE; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; MISOPROSTOL; NORETHISTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; POLYURETHAN; PROGESTERONE; SPERMICIDAL AGENT;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABORTION; ACNE; AMENORRHEA; ANOVULATION; BARRIER CONTRACEPTION; BREAKTHROUGH BLEEDING; BREAST CANCER; BREAST TENDERNESS; CANCER RISK; CLINICAL TRIAL; CONDOM; CONGENITAL HEART DISEASE; CONTRACEPTION; CORONARY ARTERY DISEASE; CYANOTIC HEART DISEASE; CYSTITIS; DEPRESSION; DEVICE INFECTION; DIAGNOSTIC PROCEDURE; DIAPHRAGM; DISEASE PREDISPOSITION; DIURESIS; EMERGENCY CONTRACEPTION; ENDOCARDITIS; FLUID RETENTION; GYNECOLOGY; HEADACHE; HEALTH STATUS; HORMONE SUBSTITUTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; IRON DEFICIENCY ANEMIA; LIPID BLOOD LEVEL; LOW DRUG DOSE; LUNG EMBOLISM; LUTEOLYSIS; MENOPAUSAL SYNDROME; MENOPAUSE; MENSTRUAL IRREGULARITY; MENSTRUATION; ORAL CONTRACEPTION; OSTEOPOROSIS; PREGNANCY; PRIORITY JOURNAL; REPRODUCTION; REVIEW; SIDE EFFECT; SKIN IRRITATION; STROKE; SURGICAL TECHNIQUE; SURVIVAL TIME; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; UTERINE TUBE LIGATION; UTERUS CARCINOMA; VAGINA BLEEDING; VAGINA DISCHARGE; VAGINA RING; VASECTOMY; WEIGHT GAIN;

EID: 13844276559     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2003.11.021     Document Type: Review

References (63)

1. Perloff J.K., Koos B. Pregnancy in congenital heart disease. The mother and the fetus. Perloff J.K., Child J.S. Congenital heart disease in the adult. 2nd ed.:1996;124-140 Saunders, Philadelphia
2. Mendelson M.A. Congenital cardiac disease and pregnancy. Clin. Perinatol. 24:1997;467-482
3. Jones G.S., Wentz A.C. Adolescence, menstruation and the climacteric. Danforth N.D. Obstetrics and gynecology. 4th ed.:1994;157-161 Lippincott, Philadelphia
4. Canobbio M.M., Rapkin A.J., Perloff J.K., Lin A., Child J.S. Menstrual patterns in women with congenital heart disease. Pediatr. Cardiol. 16:1995;12-15
5. Canobbio M.M., Mair D.D., van der Velde M., Koos B.J. Pregnancy outcomes after the Fontan repair. Am. J. Cardiol. 28:1996;763-767
6. Disaia P.J., Creasman W.T. Clinical gynecologic oncology. 5th ed.:1997;The C.V. Mosby, St. Louis, MO
7. Kurman R.J., Kaminshi P.T., Norris H.J. The behavior of endometrial hyperplasia: a long-term study of "untreated" hyperplasia in 170 patients. Cancer. 56:1985;403-412
8. Perloff J.K., Rosove M.H., Child J.S., Wright G.B. Adults with cyanotic congenital heart disease: hematologic management. Ann. Intern. Med. 109:1988;406-413
9. McGehee W. Anticoagulation in pregnancy. Elkayam U., Gleicher N. Cardiac problems in pregnancy: diagnosis and management of maternal and fetal disease. 2nd ed.:1990;397-415 Alan R. Liss, New York
10. Oakley C. Anticoagulation and pregnancy. Eur. Heart J. 16:1995;1317-1319
11. Stevenson R., Burton M., Ferlato G., Taylor H. Hazards of oral anticoagulant during pregnancy. Am. J. Med. 68:1980;122-140
12. Stroke prevention in atrial fibrillation investigators: adjusted-dose warfarin versus low intensity, fixed-dose warfarin plus aspirin for high risk patients with atrial fibrillation. Lancet. 348:1996;633-638
13. Hill J.A., Kassan S.H. Ovarian hemorrhage in ovulating women receiving anticoagulant therapy. J. Reprod. Med. 29:1984;205-208
14. Manny J., Mirin G., Rozin R.R., Freund U., Borman J.B. Ovarian hemorrhage complicating anticoagulant therapy. Obstet. Gynecol. 41:1973;512-514
15. Tresch D.D., Halverson G., Blick M., Keelan M.H. Ovarian (corpus luteum) hemorrhage during anticoagulation therapy. Ann. Intern. Med. 88:1978;642-646
16. Davis C.E., Wiley W.B., Faulconer R.J. Necrosis of the female breast complicating oral anti-coagulant treatment. Ann. Surg. 175:1972;647-656
17. Abma J.C., Chaudra A., Mosher W.D., Peterson L.S., Piccinino L.J. Fertility, family planning and women's health: new data from 1995 National Survey of Family Growth. Vital Health Stat. 23:1997;1-114
18. Henshaw S.K. Unintended pregnancy in United States. Fam. Plann. Perspect. 30:1998;24-29
19. Vessey M., Mant J., Smith A., Yeates D. Oral contraceptive and venous thromboembolism: indices in a large prospective study. BMJ. 292:1986;526
20. Beller F.K., Ebert C. Effects of oral contraceptive on blood coagulation: a review. Obstet. Gynecol. Surv. 67:1985;517-522
21. Speroff L. Oral contraceptives and arterial and venous thrombosis: a clinicians formulations. Am. J. Obstet. Gynecol. 179:1998;S25-S36
22. Hatcher R.A., Trussell J., Stewart F., Cates W., Stewart G.L., Guest F., et al. Contraception technology. 17th ed.:1998;Ardent Media, New York, NY
23. Fotherby K. The progesterone-only pill and thrombosis. Br. J. Fam. Plann. 15:1989;83
24. Speroff L., Darney P. A clinical guide for contraception. 2nd ed.:1992;Williams and Wilkins, Baltimore, MD
25. "Update on Norplant Contraceptive Kits" FDA Talk Papers. U.S. Food and Drug Administration, July 26, 2002.
26. Croxatto H.B., Makarainen L. The pharmacodynamics and efficacy of Implanon: an overview of the data. Contraception. 58:1998;91S-97S
27. Cundy T., Evan M., Roberts H., Wattie D., Ames R., Reid I.R. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ. 303:1991;13-16
28. Cromer B.A., Blair J.M., Mahan J.D., Zibners L., Naumovski Z. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgesterel (Norplant), or oral contraceptives. J. Pediatr. 129:1996 (Nov);671-676
29. Kaunitz A.M., Garceau R.J., Cromie M.A. Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiolcypionate injectable suspension) and Ortho-Novum oral contraceptive (norethendrone/ethinyl estradioltriphasic). Contraception. 60:1999;179-187
30. Cery H.W. A review of the association between intrauterine devices and acute pelvic inflammatory disease. J. Reprod. Med. 20:1978;200-215
31. Farley T.M.M., Rosenberg M.J., Rowe P.J., Chen J.H., Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 339:1992;785-788
32. Lee N.C., Rubin G.L., Borucki R. The intrauterine device and pelvic inflammatory disease revisited: new results from the Women's Health Study. Obstet. Gynecol. 72:1988;1-6
33. Seaworth J., Durack D.T. Infective endocarditis in obstetric and gynecologic practice. Am. Obstet. Gynecol. 154:1986;180-188
34. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease Prevention of bacterial endocarditis: recommendations by the American heart association. JAMA. 277:1997;1794-1801
35. French R.S., Cowan F.M., Mansour D., Higgins J.P., Robinson A., Procter T., et al. Levonorgestre-releasing (20 microgram/day) intrauterine systems (Mirena) compared with other methods of reversible contraceptives. BJOG. 107:2000;1218-1225
36. US Food and Drug Administration. FDA approves first hormonal vaginal contraceptive ring. Available: http://www.fda.gov/bbs/topics/Answers/2001/ ANSO2207.html. Accessed November 12,2001.
37. Timmer C.J., Mulders T.M. Pharmacokinetics of etonogestrel and ethinyl estradiol released from a combined contraceptive vaginal ring. Clin. Pharmacokinet. 39:2000;142-233
38. Audet M.C., Moreau M., Koltum W., et al. Evaluation of contraceptive efficacy and cycle control of transdermal contraceptive patch vs. an oral contraceptive. JAMA. 285:2001;2347-2354
39. Craig S., Hepburn S. The effectiveness of barrier methods of contraception with and without spermicide. Contraception. 26:1982;347-359
40. Kestelman P., Trussell J. Efficacy of the simultaneous use of condoms and spermicides. Fam. Plann. Perspect. 23:1991;226-227
41. Xie C.X., Piecoro L.T., Wermeling D.P. Gender-related considerations in clinical pharmacology and drug therapeutics. Crit. Care Nurs. Clin. North Am. 9:1997;459-468
42. Randomized controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception. Task Force on Postovulatory Methods of Fertility Regulation. Lancet. 352:1998;428-433
43. Ho P.C., Kwan M.S. A prospective randomized comparison of levonorgestrel with the Yuzpe regimen in post-coital contraception. Hum. Reprod. 352(8):1993;389-392
44. Grimes D.A., Raymond E.G. Emergency contraception. Ann. Intern. Med. 137:2002;180-189
45. Snabes M.C., Paindexter A.N. Laparoscoptic tubal legalism under direct anesthesia in women with cyanotic heart disease. Obstet. Gynecol. 78:1991 (Sept.);437-440
46. Weaver K., Glasier A. Interaction between broad-spectrum antibiotics and the combined oral contraceptive pill. A literature review. Contraception. 59:1999;71-78
47. Donaly T.G., Smith R.F., Roy B. Reduced oral contraceptive effectiveness with concurrent antibiotic use: a protocol for prescribing antibiotics to women of childbearing age. Compendium. 11:1990;392-396
48. Winikoff B., Wymelenberg S. The whole truth about contraception. 1998;Joseph Henry Press
49. Back D.J., Orme M.L. Pharmacokinetic drug interactions with oral contraceptives. Clin. Pharmacokinet. 18:1990;472-484
50. Crawford P., Chadwick D.J., Martin C., Tija J., Back D.J., Orme M. The interaction of pheytoin and carbamazepine with combined oral contraceptive steroids. J. Clin. Pharmacol. 30:1990;892-896
51. FDA Approval of mifepristone: an overview. Contracept. Rep. 11:2000;4-12
52. Spitz I.M., Bardin C.W., Benton L., et al. Early pregnancy termination with mifepristone and misoprostol in the United States. N. Engl. J. Med. 333:1998;1242-1247
53. Taussig H.B., Kallman C.H., Nagel D., et al. Longterm observations on the Blalock Taussig operation: VIII. 20 to 28 year follow-up on patients with a tetralogy of Fallot. John Hopkins Med. J. 137:1975;13-19
54. Swan L., Hillis W.S., Cameron A. Family planning requirements of adults with congenital heart disease. Heart. 78:1997;9-11
55. Warnes A., Liberthsen R. Task Force I: changing profile of congenital heart disease in adult life. 32nd Bethesda Conference: care of the adult with congenital heart disease. JACC. 37:2001;1170-1175
56. Thacker H.L. Menopause. Women's Health. 24:1997;205-221
57. The Writing Group for PEPI Trial Effects of estrogen or estrogen-progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 273:1995;199-208
58. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen and progestin for secondary prevention of coronary heart disease in women (HERS). JAMA. 280:1998;605-613
59. Vastag B. Hormone replacement therapy falls out of favor with expert committee. JAMA. 287:2002;1923-1924
60. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in health postmenopausal women: principle results from the Women's Health Initiative randomized controlled trial. JAMA. 288:2002;321-333
61. Col N.F., Eckman M.H., Karas R.H., et al. Patient specific decisions about hormone replacement therapy in postmenopausal women. JAMA. 277:1997;1140-1147
62. Utian W.H., Shoupe D., Bachmann G., Pinkerton J.V., Pickar J.H. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil. Steril. 75:2001;1065-1079
63. American College of Physicians Guidelines for counseling postmenopausal women about preventive hormone therapy. JABFP. 6:1993;159-162